Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

21. Massage for preventing postpartum constipation: a systematic review and meta-analysis

Massage for preventing postpartum constipation: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

22. Effect of electroacupuncture treatment on functional constipation in adults: a systematic review protocol

Effect of electroacupuncture treatment on functional constipation in adults: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

23. Constipation in children

Constipation in children Constipation in children - NICE CKS Share Constipation in children: Summary Constipation is a decrease in the frequency of bowel movements characterized by the passing of hardened stools which may be large and associated with straining and pain. Normal stool frequency in children ranges from an average of 4 per day in the first week of life to 2 per day at 1 year of age. Passing between 3 stools per day and 3 per week is usually attained by 4 years of age. Constipation (...) is termed idiopathic (functional) if it cannot be explained by any anatomical or physiological abnormality. Contributing factors for constipation include pain, fever, inadequate fluid intake, reduced dietary fibre intake, toilet training issues, the effects of drugs, psychosocial issues, and a family history of constipation. Two or more of the following clinical features indicate that a child is constipated: Fewer than three complete stools per week (unless exclusively breastfed, when stools may

2019 NICE Clinical Knowledge Summaries

24. Constipation

Constipation Constipation - NICE CKS Share Constipation: Summary Constipation is a symptom-based disorder which describes defecation that is unsatisfactory because of infrequent stools, difficulty passing stools, or the sensation of incomplete emptying. The Rome IV diagnostic criteria for constipation include spontaneous bowel movements occurring less than three times a week. Chronic constipation usually describes symptoms which are present for at least 12 weeks in the preceding six months (...) . Faecal loading/impaction describes retention of faeces to the extent that spontaneous evacuation is unlikely. Functional (primary or idiopathic)constipation is chronic constipation without a known cause. Secondary (organic) constipation is constipation caused by a drug or underlying medical condition. Constipation may occur at any age but is more common in women, the elderly, and during pregnancy. Assessment of a person with constipation should include: Any red flag symptoms or signs that may suggest

2019 NICE Clinical Knowledge Summaries

25. Acupuncture at Tianshu (ST25) for functional constipation: a systematic review and meta-analysis

Acupuncture at Tianshu (ST25) for functional constipation: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

26. Auricular point taping for constipation in patients with stroke: a cumulative meta-analysis

Auricular point taping for constipation in patients with stroke: a cumulative meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

27. Placebo response rate in patients with chronic constipation

Placebo response rate in patients with chronic constipation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

28. Prucalopride (Motegrity) - To treat chronic idiopathic constipation

Prucalopride (Motegrity) - To treat chronic idiopathic constipation Drug Approval Package: Motegrity (prucalopride) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Motegrity (prucalopride) Company: Shire Development LLC Application Number: 210166 Approval Date: 12/14/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2019 FDA - Drug Approval Package

29. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis Full Text available with Trip Pro

Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis Several secretagogues have been approved for the treatment of irritable bowel syndrome with constipation (IBS-C). However, their relative efficacy is unclear because there have been no head-to-head randomized controlled trials. We conducted a network meta-analysis to compare their efficacies in patients with IBS-C.We searched MEDLINE, EMBASE, EMBASE Classic

2019 EvidenceUpdates

30. A systematic review and meta-analysis of the efficacy of probiotics in the treatment of functional constipation in children

A systematic review and meta-analysis of the efficacy of probiotics in the treatment of functional constipation in children Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

31. Acupressure effect on constipation: systematic review and meta-analysis

Acupressure effect on constipation: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2019 PROSPERO

32. Diagnosis, Assessment and Management of Constipation in Advanced Cancer: ESMO Clinical Practice Guidelines

Diagnosis, Assessment and Management of Constipation in Advanced Cancer: ESMO Clinical Practice Guidelines CLINICAL PRACTICE GUIDELINES Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines † P. J. Larkin 1,2 , N. I. Cherny 3 , D. La Carpia 4 , M. Guglielmo 5 , C. Ostgathe 6 , F. Scotte ´ 7 & C. I. Ripamonti 5 ,on behalf of the ESMO Guidelines Committee * 1 School of Nursing, Midwifery and Health Systems, University College Dublin, Dublin; 2 (...) Department of Medical Oncology and Supportive Care, Foch Hospital, Suresnes, France *Correspondence to: ESMO Guidelines Committee, ESMO Head Of?ce, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: March 2018. Introduction Constipation is a common problem in patients with advanced can- cer and a signi?cant source of major morbidity and distress, which is often under-appreciated [1]. Constipation is subjectively experi- enced

2018 European Society for Medical Oncology

33. Constipation

Constipation Constipation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Constipation Last reviewed: February 2019 Last updated: October 2018 Summary A detailed history and physical examination, including a digital rectal examination, is the first step in the evaluation of constipation. Diagnostic evaluation may include a colonoscopy if indicated, colonic transit study, anorectal manometry, and a balloon expulsion (...) study. Initial treatment consists of lifestyle modification and laxatives. Medical treatment should be tailored to the underlying aetiology. Patients who do not respond to medical treatment may need specialised evaluation for pelvic floor dysfunction and biofeedback therapy. Surgery is only rarely indicated. Definition Chronic constipation is a polysymptomatic heterogeneous disorder. Patients define constipation on the basis of excessive straining, a sense of incomplete evacuation, failed or lengthy

2018 BMJ Best Practice

34. Constipation

Constipation Top results for constipation - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for constipation The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

35. Constipation

Constipation Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading

2018 Trip Evidence Maps

36. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis Full Text available with Trip Pro

Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis Opioids are increasingly prescribed in the West and have deleterious GI consequences. Pharmacological therapies to treat opioid-induced constipation (OIC) are available, but their relative efficacy is unclear. We performed a systematic review and network meta-analysis to address this deficit in current knowledge.We searched MEDLINE, EMBASE, EMBASE Classic

2018 EvidenceUpdates

37. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials (Abstract)

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials Two identical, phase 3, randomized, double-blind, placebo-controlled trials evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C).Adults meeting Rome III criteria for IBS-C were randomized (1:1:1) to placebo or plecanatide (3 or 6 mg) for 12 weeks. The primary efficacy end (...) across both studies. All secondary end points (stool frequency/consistency, straining, abdominal symptoms) showed statistically significant improvements compared with placebo. The most common AE was diarrhea (3 mg, 4.3%; 6 mg, 4.0%; placebo, 1.0%). Discontinuation due to diarrhea was infrequent (3 mg, 1.2%; 6 mg, 1.4%; placebo, 0).Plecanatide significantly improved both abdominal pain and constipation symptoms of IBS-C with minimal associated side effects and high levels of tolerability.

2018 EvidenceUpdates

38. Management of constipation in patients with Parkinson’s disease Full Text available with Trip Pro

Management of constipation in patients with Parkinson’s disease A considerable body of research has recently emerged around nonmotor symptoms in Parkinson's disease (PD) and their substantial impact on patients' well-being. A prominent example is constipation which occurs in up to two thirds of all PD-patients thereby effecting psychological and social distress and consequently reducing quality of life. Despite the significant clinical relevance of constipation, unfortunately little knowledge (...) exists on effective treatments. Therefore this systematic review aims at providing a synopsis on clinical effects and safety of available treatment options for constipation in PD. For this purpose, three electronic databases (MEDLINE, EMBASE, PsycINFO) were searched for experimental and quasi-experimental studies investigating the efficacy/effectiveness of interventions in the management of PD-associated constipation. Besides, adverse events were analyzed as secondary outcome. In total, 18

2018 NPJ Parkinson's disease

39. Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects Full Text available with Trip Pro

Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects Daikenchuto (DKT) is a Kampo medicine used for the treatment of constipation. In this study, we evaluated the effectiveness of DKT against constipation.Thirty-three patients administered DKT for constipation were selected and divided into low-dose (7.5 g DKT; n = 22) and high-dose (15 g DKT; n = 11) groups. We retrospectively evaluated weekly defaecation frequency, side effects, and clinical (...) ) and second (P = 0.0101) weeks, respectively. There was no significant change in clinical laboratory values.We suggest that DKT increases defaecation frequency and is safe for treating constipation.

2018 International journal of chronic diseases

40. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis (Abstract)

Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis Linaclotide and plecanatide are guanylate cyclase-C (GCC) agonists for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Our objective is to evaluate the efficacy and tolerability of GCC agonists based on data from multiple randomized controlled trials (RCTs

2018 EvidenceUpdates